Macrocure, a late-stage Israeli biotech developing white blood cell injections to treat hard-to-heal wounds, announced terms for its IPO on Friday. The Petach Tikva, Israel-based company plans to raise $75 million by offering 5.4 million shares at a price range...read more
Macrocure, a late-stage Israeli biotech developing white blood cell injections to treat hard-to-heal wounds, filed on Monday with the SEC to raise up to $75 million in an initial public offering. The Petach Tikva, Israel-based company, which was founded in 2008,...read more
MediWound, which is developing treatments for severe burns and other hard-to-heal wounds, raised $70 million by offering 5.0 million shares at $14, the low end of the $14 to $16 range. MediWound plans to list on the NASDAQ under the symbol MDWD. Credit Suisse,...read more
Israeli white blood cell biotech Macrocure sets terms for $75 million IPO
Macrocure, a late-stage Israeli biotech developing white blood cell injections to treat hard-to-heal wounds, announced terms for its IPO on Friday. The Petach Tikva, Israel-based company plans to raise $75 million by offering 5.4 million shares at a price range...read more
Israeli white blood cell biotech Macrocure files for a $75 million IPO
Macrocure, a late-stage Israeli biotech developing white blood cell injections to treat hard-to-heal wounds, filed on Monday with the SEC to raise up to $75 million in an initial public offering. The Petach Tikva, Israel-based company, which was founded in 2008,...read more
MediWound prices IPO at $14, the low end of the range
MediWound, which is developing treatments for severe burns and other hard-to-heal wounds, raised $70 million by offering 5.0 million shares at $14, the low end of the $14 to $16 range. MediWound plans to list on the NASDAQ under the symbol MDWD. Credit Suisse,...read more
9 US IPOs planned for the week of Mar 17
The following IPOs are expected to price this week: A10 Networks (ATEN), which provides software-based appliances that optimize data center performance, plans to raise...read more